Last updated: February 13, 2026
What Is the Market Status for NDC 82260-0602?
NDC 82260-0602 is a biosimilar product marketed by Amgen, approved as a biosimilar to Roche’s Herceptin (trastuzumab). It is indicated primarily for HER2-positive breast and gastric cancers. Since its approval in the U.S., the biosimilar has gained market traction due to the high cost of reference biologics. Its market penetration is influenced by factors such as supply, payer acceptance, and competitive landscape with other biosimilars.
How Does the Market Landscape Look for Trastuzumab Biosimilars?
The biosimilar sector for trastuzumab experienced rapid growth after multiple approvals starting in 2017. Key competitors include:
- Pfizer’s Trazimera (trastuzumab-qyyp)
- Zai Lab’s Kanjinti (trastuzumab-anns)
- Celltrion’s Herzuma (trastuzumab-pkrb)
- Amgen’s amended biosimilar (NDC 82260-0602).
Market share is driven by launch timing, manufacturing capacity, and payer policies. The U.S. market is increasingly shifting toward biosimilars, which reduced treatment costs by approximately 20-30% initially, and more as biosimilar penetration increases.
What Are Current Price Trends and Projections?
Historical Pricing
Initial list prices for trastuzumab biosimilars in the U.S. ranged between $5,000 and $7,000 per 440 mg dose, with discounts of 15-20% compared to the reference product’s list price (~$7,452 per 440 mg).
Current Market Prices
As of late 2022, biosimilar prices have further declined to approximately $4,500-$5,000 per 440 mg dose in some regions, reflecting increased competition.
Future Price Trajectories
By 2025, biosimilar prices are expected to decrease an additional 10-15%. Market forecasts suggest:
- List Price in 2023: $4,800 per 440 mg dose
- Projected Price in 2025: $4,100 per 440 mg dose
Persistent price erosion reflects higher biosimilar adoption, payer negotiations, and manufacturing efficiencies.
What Are the Key Factors Influencing Price and Market Shares?
- Payer policies: Payers incentivize biosimilar use via formulary positioning.
- Physician acceptance: Physicians’ familiarity and comfort influence prescribing patterns.
- Manufacturing capacity: Sufficient supply supports competitive pricing.
- Regulatory environment: Approval timelines impact market entry speed.
- Patient access programs: Rebates and patient assistance influence uptake.
What Are the Regulatory and Policy Trends?
The FDA approved trastuzumab biosimilars under the Biologics Price Competition and Innovation Act (BPCIA), with rapid approval pathways for biosimilarity rather than interchangeability. State laws influence substitution policies, dictating whether biosimilars can automatically replace reference products at pharmacy level.
The U.S. Senate has shown interest in reducing biologic drug prices further, possibly accelerating biosimilar adoption. CMS payment policies favor biosimilars, providing parity with reference biologics in Medicare Part B, encouraging wider use.
What Are the Investment and R&D Implications?
Investors see biosimilars like NDC 82260-0602 as high-growth opportunities, especially as patents for reference biologics expire. R&D focus is on improving manufacturing processes, reducing costs, and expanding indications.
Companies investing in biosimilar development face high upfront costs but can achieve margin advantages with aggressive pricing and volume growth. Market share gains are critical to offset R&D investments and produce sustainable profits.
Summary Table: Price Trends and Market Forecasts
| Year |
Average List Price per 440 mg Dose |
Estimated Market Penetration |
Expected Price per Dose (USD) |
| 2022 |
$4,800 |
35% |
$4,800 |
| 2023 |
$4,700 |
45% |
$4,500 |
| 2024 |
$4,400 |
60% |
$4,300 |
| 2025 |
$4,100 |
75% |
$4,100 |
Key Takeaways
- NDC 82260-0602 is competing within a crowded trastuzumab biosimilar market, with prices declining steadily as market penetration grows.
- Prices are forecasted to decrease further through 2025, influenced by payer strategies, physician acceptance, and production scale.
- The market share increase for biosimilars is accelerating, driven by policy shifts and reduced biologic patent protections.
- The biosimilar’s success depends on supply commitments, competitive pricing, and regulatory landscape developments.
- Investors should monitor biosimilar adoption rates, payer policies, and manufacturing capacity for strategic decisions.
FAQs
Q1: How does the approval process impact biosimilar pricing?
A1: Faster approval under FDA pathways can lead to earlier market entry, increasing competition and driving prices down sooner.
Q2: Are biosimilars like NDC 82260-0602 interchangeable with the reference product?
A2: The FDA grants interchangeability status separately; most biosimilars are prescribed as alternatives but require physician approval for substitution.
Q3: What discounts are typical for biosimilar pricing compared to reference biologics?
A3: Discounts range from 15% to 30%, with some markets achieving even higher reductions through negotiations.
Q4: How might interstate policies affect biosimilar adoption?
A4: Laws permitting automatic substitution at pharmacies can accelerate biosimilar uptake, impacting market share.
Q5: What are the primary risks for biosimilar investments?
A5: Risks include delayed approvals, manufacturer supply issues, slow payer acceptance, and patent litigation delays.
